Key result
Modified Xiaoyao Powder will be evaluated in a planned randomized controlled trial of 280 patients to determine its efficacy in reducing depressive symptoms in patients with COPD and mild to moderate depression.
Why the study?
Depression is a common, burdensome complication of COPD linked to exacerbations and mortality, but comorbid mood symptoms often go undiagnosed and undertreated in clinical practice.
Does Modified Xiaoyao Powder improve depression symptoms in patients with COPD and comorbid mild to moderate depression?
RCT (n=280)
Double-blind
Computer-controlled system, 1:1 ratio
No
Does Modified Xiaoyao Powder improve depression symptoms in patients with COPD and comorbid mild to moderate depression?
This study protocol outlines a randomized controlled trial to evaluate whether Modified Xiaoyao Powder, combined with psychotherapy and standard COPD care, improves depressive symptoms in patients with COPD.
Answers are grounded in this paper and cite their sources.
Short-term escitalopram reduces depression and anxiety in COPD; extends RCT evidence and supports targeted pharmacotherapy integration.
INTRODUCTION: Depression is an important complication of chronic obstructive pulmonary disease (COPD), occurring in more than one-third of individuals with COPD, and its severity is closely related to the severity and acute exacerbation of COPD, significantly contributing to the risk of death from COPD. Comorbid depression in COPD can be a burden on COPD-related diseases by reducing quality of life and compliance with treatment. Unfortunately, symptoms of COPD combined anxiety and depression are not properly diagnosed and treated in clinical practice, especially in the early stages of mood changes in patients with COPD, as the symptoms are mild and monotonous, and are overlooked. METHODS: In this prospective, randomized, placebo-controlled trial, we will assigned 280 eligible patients who had COPD combined depression to receive either Modified Xiaoyao Powder (MXP) or placebo. The primary end point is the change in the Hamilton Depression Scale (17 items) (HAMD-17) score from baseline on weeks 4, 12, and 24. DISCUSSION: Six months of MXP for COPD combined mild to moderate depression may alleviate the symptoms of depression, reduce the frequency of hospitalizations, the number of exacerbations, and improve the compliance of treatment. TRIAL REGISTRATION: ChiCTR2000038741.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2020) conducted an RCT in Chronic obstructive pulmonary disease (COPD) combined with mild to moderate depression (n=280). Modified Xiaoyao Powder vs. Placebo was evaluated on Change in the Hamilton Depression Scale (17 items) (HAMD-17) score from baseline on weeks 4, 12, and 24. Modified Xiaoyao Powder will be evaluated in a planned randomized controlled trial of 280 patients to determine its efficacy in reducing depressive symptoms in patients with COPD and mild to moderate depression.
Synapse has enriched 10 related papers. Consider them for comparative context: